Skip to main content

Table 2 eRAPID RT study questionnaires and Case Report Forms (CRFs): participant completed

From: eRAPID electronic patient self-Reporting of Adverse-events: Patient Information and aDvice: a pilot study protocol in pelvic radiotherapy

Questionnaire/CRF

Description of time points for completion

Baseline

3 weeks

6 weeks

9 weeks

12 weeks

18 weeks

24 weeks

Consent form

Baseline

X

      

Baseline: patient sociodemographic data form

Baseline

X

      

Baseline: computer usage questionnaire

Baseline

X

      

Patient-reported eRAPID symptom questionnaire

(eRAPID intervention arm only)

Within 24 h of study entry and weekly during treatment and 6 weeks afterwards (12 weeks total). Then at 18 and 24 weeks.

X weekly

X weekly

X weekly

X weekly

X weekly

X (except rectal)

X (except rectal)

Patient Outcome Measures

 FACT-G

 EORTC-QLQ-C30

 EQ-5D-5 L

Baseline, 6, 12 and 24 weeks

X

 

X

 

X

 

X

 Self-efficacy, Lorig 6-item

Baseline and 12 weeks

X

   

X

  

 Patient Activation Measure (PAM)

Baseline and 12 weeks

X

   

X

  

 Use of resources form

6, 12 and 24 weeks

  

X

 

X

 

X

 System Usability Scale

24 weeks (eRAPID intervention arm only)

      

X

Participant withdrawal feedback form

At point of withdrawal

       

End of study patient questionnaire

24 weeks

      

X

Clinician questionnaires

 Clinician eRAPID feedback form (eRAPID intervention arm only)

At routine hospital appointments throughout the study

 

X

X

X

X

X (except rectal)

X (except rectal)

 Clinician record of CTCAE

To be completed by clinician at the follow-up appointment 4–6 weeks after completion of treatment (exact time-point will be different for different disease groups)

      Â